Details
Stereochemistry | ACHIRAL |
Molecular Formula | CH2O |
Molecular Weight | 30.026 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C=O
InChI
InChIKey=WSFSSNUMVMOOMR-UHFFFAOYSA-N
InChI=1S/CH2O/c1-2/h1H2
Molecular Formula | CH2O |
Molecular Weight | 30.026 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB03843Curator's Comment: description was created based on several sources, including
https://www.nap.edu/read/13142/chapter/6 |
https://www.drugs.com/pro/formaldehyde-liquid.html
Sources: https://www.drugbank.ca/drugs/DB03843
Curator's Comment: description was created based on several sources, including
https://www.nap.edu/read/13142/chapter/6 |
https://www.drugs.com/pro/formaldehyde-liquid.html
Formaldehyde is a naturally occurring organic compound, and an important industrial precursor to many other materials and organic compounds. Formaldehyde solution (formalin) is used as a disinfectant. Formaldehyde vapors are toxic, upon entry formaldehyde reacts readily with macromolecules, including DNA to form DNA-protein and DNA-DNA cross-links.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3796657 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | FORMALDEHYDE 10% Approved UseDrying agent for pre and post surgical removal of warts, or for non-surgical laser treatment of warts where dryness is required. Safeguards against offensive odor and dries excessive moisture of feet. Not to be used in patients known to be sensitive to any of the ingredients in this product. |
PubMed
Title | Date | PubMed |
---|---|---|
Intravesical formalin for the control of intractable bladder hemorrhage secondary to cystitis or cancer. | 1975 Oct |
|
Endodontic treatment of permanent teeth in children with a new calcium-carbamide-formaldehyde paste. | 2002 |
|
Sensitizing capacity of two monomeric aldehyde components in p-tert-butylphenol-formaldehyde resin. | 2002 |
|
Formaldehyde enhances mite allergen-induced eosinophilic inflammation in the murine airway. | 2002 |
|
IgE-mediated urticaria from formaldehyde in a dental root canal compound. | 2002 |
|
Domestic exposure to formaldehyde significantly increases the risk of asthma in young children. | 2002 Aug |
|
Contact dermatitis to phenol-formaldehyde resin in two plywood factory workers. | 2002 Aug |
|
Morphine microinjections into the rat nucleus submedius depress nociceptive behavior in the formalin test. | 2002 Aug 9 |
|
Results of long-term experimental studies on the carcinogenicity of formaldehyde and acetaldehyde in rats. | 2002 Dec |
|
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. | 2002 Nov |
|
Expression of cytokine mRNAs in mice cutaneously exposed to formaldehyde. | 2002 Oct 21 |
|
A role for peripheral somatostatin receptors in counter-irritation-induced analgesia. | 2003 |
|
Glutaraldehyde-induced and formaldehyde-induced allergic contact dermatitis among dental hygienists and assistants. | 2003 Aug |
|
The L-arginine/nitric oxide/cyclic-GMP pathway apparently mediates the peripheral antihyperalgesic action of fentanyl in rats. | 2003 Dec |
|
Potentiation of allergic bronchoconstriction by repeated exposure to formaldehyde in guinea-pigs in vivo. | 2003 Dec |
|
Contact dermatitis from electrocardiograph-monitoring electrodes: role of p-tert-butylphenol-formaldehyde resin. | 2003 Feb |
|
Structure-function relationships in human Class III alcohol dehydrogenase (formaldehyde dehydrogenase). | 2003 Feb 1 |
|
Formaldehyde application for haemorrhagic radiation-induced proctitis: a clinical and histological study. | 2003 Jan |
|
[Formaldehyde exposure levels and exposure control measures during an anatomy dissecting course]. | 2003 Jun |
|
Formaldehyde-induced gene expression in F344 rat nasal respiratory epithelium. | 2003 May 1 |
|
[Effects of formaldehyde on germ cells of male mice]. | 2003 Nov |
|
Extended follow-up of a cohort of british chemical workers exposed to formaldehyde. | 2003 Nov 5 |
|
Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. | 2003 Oct |
|
Combined effects of tumor promoters and serum on proliferin mRNA induction: a biomarker sensitive to saccharin, 2,3,7,8-TCDD, and other compounds at minimal concentrations promoting C3H/10T1/2 cell transformation. | 2003 Oct 24 |
|
Pathological effects of formalin (37% formaldehyde) mixed in feed or administered into the crops of White Leghorn cockerels. | 2003 Sep |
|
Antinociceptive profile of (-)-spectaline: a piperidine alkaloid from Cassia leptophylla. | 2003 Sep |
|
Inhalation of low-level formaldehyde enhances nerve growth factor production in the hippocampus of mice. | 2004 |
|
Multiple formaldehyde oxidation/detoxification pathways in Burkholderia fungorum LB400. | 2004 Apr |
|
Differential immunogenic and neurogenic inflammatory responses in an allergic mouse model exposed to low levels of formaldehyde. | 2004 Apr 1 |
|
Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. | 2004 Apr 26 |
|
Protein associated with Myc (PAM) is involved in spinal nociceptive processing. | 2004 Feb |
|
Reproducibility of patch tests: comparison of identical test allergens from different commercial sources. | 2004 Jan |
|
Effect of prolonged exposure to low concentrations of formaldehyde on the corticotropin releasing hormone neurons in the hypothalamus and adrenocorticotropic hormone cells in the pituitary gland in female mice. | 2004 Jul 2 |
|
Allergic contact sensitivity in elderly patients. | 2004 Jun |
|
Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. | 2004 Jun |
|
Biodegradation of alachlor by soil streptomycetes. | 2004 Jun |
|
Mortality from solid cancers among workers in formaldehyde industries. | 2004 Jun 15 |
|
Evidence for the involvement of vanilloid receptor in the antinociception produced by the dialdeydes unsaturated sesquiterpenes polygodial and drimanial in rats. | 2004 Mar |
|
Investigations into the antinociceptive activity of Sapindus trifoliatus in various pain models. | 2004 May |
|
The implausibility of leukemia induction by formaldehyde: a critical review of the biological evidence on distant-site toxicity. | 2004 Oct |
|
Use of the platelet reactivity index by Grotemeyer, platelet function analyzer, and retention test Homburg to monitor therapy with antiplatelet drugs. | 2005 |
|
Transcriptomic analysis of F344 rat nasal epithelium suggests that the lack of carcinogenic response to glutaraldehyde is due to its greater toxicity compared to formaldehyde. | 2005 |
|
Protective effect of NAC on formaldehyde-containing-ZOE-based root-canal-sealers-induced cyclooxygenase-2 expression and cytotoxicity in human osteoblastic cells. | 2005 Aug |
|
Methanol, formaldehyde, and sodium formate exposure in rat and mouse conceptuses: a potential role of the visceral yolk sac in embryotoxicity. | 2005 Feb |
|
An ecological study of the association of environmental chemicals on breast cancer incidence in Texas. | 2005 Jul |
|
Contact sensitivity to preservatives in Turkey. | 2005 Jun |
|
[Study on differential display genes of tolerant-damage of MRC-5 induced by formaldehyde of low dose]. | 2005 May |
|
Thrombotic thrombocytopenic purpura causing rapid unexpected death: value of CD61 immunohistochemical staining in diagnosis. | 2005 May-Jun |
|
Detection of chlamydial bodies and antigens in the central nervous system of patients with multiple sclerosis. | 2005 Oct 1 |
|
Identification of N,N-dimethylamphetamine formed by methylation of methamphetamine in formalin-fixed liver tissue by multistage mass spectrometry. | 2006 Mar 10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/formaldehyde-liquid.html
Formaldehyde 10% solution is applied topically once a day to affected areas.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3796657
Human lymphoblasts were exposed in vitro to various concentrations of formaldehyde (HCHO) in single and multiple treatment regimens to determine relative mutagenic efficiency. HCHO treatment resulted in a significant nonlinear increase in DNA-protein crosslinks at concentrations greater than 50 uM X 2 h, which correlated with the onset of significant toxicity in this cell line.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:16:56 GMT 2025
by
admin
on
Mon Mar 31 18:16:56 GMT 2025
|
Record UNII |
1HG84L3525
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QP53AX19
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
||
|
NCI_THESAURUS |
C45175
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
||
|
IARC | Formaldehyde | ||
|
NCI_THESAURUS |
C94714
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
||
|
CFR |
21 CFR 173.340
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
||
|
CFR |
21 CFR 175.210
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
formaldehyde
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
N0000171131
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
50-00-0
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
1HG84L3525
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
3244
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
314636
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
ALTERNATIVE | |||
|
FORMALDEHYDE
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
C29744
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
Formaldehyde
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
100000092801
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
DTXSID7020637
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
m5533
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
16842
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
61538
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
N0000184306
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
712
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
31962
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
298885
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
N0000175629
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
CHEMBL1255
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
1HG84L3525
Created by
admin on Mon Mar 31 18:16:57 GMT 2025 , Edited by admin on Mon Mar 31 18:16:57 GMT 2025
|
PRIMARY | |||
|
DB03843
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
D005557
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
SUB12505MIG
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
4530
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY | |||
|
200-001-8
Created by
admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE TOXIC |
Formed from breakdown of hydroxymethylmethylnitrosamine can alkylate DNA
|
||
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|